Next Generation Sequencing
- Pan-Cancer Cell-Free Assay
- Cancer-Specific Assays (lung, breast, colon, myeloid, pediatric)
- Tumor Mutation Burden Assay
- Immune Response Assay
- Immune Repertoire for TCR Beta Assay
We use all tools necessary to help navigate the complexity of cancer. Working alongside our biopharma partners, we boldly question the status quo and employ personalized and integrated approaches to uncover new solutions to diagnostic challenges with industry-leading expertise in blood-based assays.
Our diagnostic solutions leverage both genomics and proteomics to uncover comprehensive insights about the tumor biology and patient’s immune response to therapeutics in clinical development. We take a technology agnostic approach for blood-based biomarker discovery to ensure we provide the necessary solutions to fulfill your needs.
Our biomarker discovery projects include discovering novel biomarker tests with machine learning, developing assays for known biological targets, retrospectively gathering insights from your clinical studies, and prospectively enrolling patients into your clinical trials. We follow a simple biomarker evaluation process to ensure your diagnostic solutions are CDx ready.